A phase i study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 243-249

  Richter, Suzanne ^a   Bedard, Philippe L ^a   Chen, Eric Xueyu ^a   Clarke, Blaise A ^b   Tran, Ben ^a   Hotte, Sebastien J ^c   Stathis, Anastasios ^a   Hirte, Hal W ^c   Razak, Albiruni R A ^a   Reedijk, Michael ^a   Chen, Zhuo ^b   Cohen, Brenda ^b   Zhang, Wen Jiang ^a   Wang, Lisa ^a   Ivy, S Percy ^d   Moore, Malcolm J ^a   Oza, Amit M ^a   Siu, Lillian L ^a   McWhirter, Elaine ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Notch inhibition; Phase I; RO4929097

Indexed keywords

ANGIOGENIC FACTOR; GAMMA SECRETASE INHIBITOR; GEMCITABINE; MITOMYCIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NITROSOUREA; NOTCH3 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIMARY TUMOR; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIGNAL TRANSDUCTION; SOLID TUMOR; TRACHEA CANCER; TREATMENT RESPONSE;

ADULT; AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAZEPINES; CALCIUM-BINDING PROTEINS; DEOXYCYTIDINE; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; RECEPTOR, NOTCH1; RECEPTORS, NOTCH;

EID: 84896391556     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9965-4     Document Type: Article

References (23)

1. Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313-323
2. Bolos V, Grego-Bessa J, de la Pompa JL (2007) Notch signaling in development and cancer. Endocr Rev 28:339-363
3. Jarriault S, Le Bail O, Hirsinger E, Pourquie O, Logeat F, Strong CF et al (1998) Delta-1 activation of Notch-1 signaling results in HES-1 transactivation. Mol Cell Biol 18(12):7423-7431
4. Klinakis A, Szabolcs M, Politi K, Golde T, Osborne B, Miele L (2006) Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 103:9262-9267
5. Rizzo P, Osipo C, Foreman K et al (2008) Rationale targeting of Notch signaling in cancer. Oncogene 27:5124-5131
6. Dufraine J, Funahashi Y, Kitajewski J (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27:5132-5137
7. Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196-208
8. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV et al (2009) Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136:1741-1749 e6
9. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D et al (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69:7672-7680
10. Tolcher A, Messersmith W, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348-2353
11. Wu J, Lorusso PM, Matherly LH, Li J (2012) Implications of plasma protein binding for pharmacokinetcs and pharmacodynamics of the g-secretase inhibitor RO4929097. Clin Cancer Res 18(7):2066-2079
12. Van Moorsel C, Peters GJ, Pinedo HM (1997) Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2:127-134
13. Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL (2012) Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 209(3):437-444
14. Carmeliet P, DeSmet F, Loges S, Mazzone M (2009) Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6:315-e326
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
16. Zhang W, Seymour L, Chen EX (2008) Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatography B 876:277-282
17. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155-168
18. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE et al (2007) High-lvel JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20:685-693
19. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB et al (2008) JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111:439-448
20. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G et al (2012) A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 48(7):997-1003
21. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P et al (2011) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30(19):2307-2313
22. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD et al (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92:1355-e1357
23. He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X et al (2011) High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the g-secretase inhibitor, RO4929097. Mol Oncol 5(3):292-301